IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Annual and Extraordinary General Meeting of shareholders in Zaventem today. The shareholders approved all agenda items of the Annual General Meeting, including the financial statements for the financial year ended 31 December 2011.
